



## **COREMEDIC ANNOUNCES PARTNERSHIP WITH INNORA FOR CLINICAL DEVELOPMENT OF THE TRANSCATHETER MITRAL VALVE REPAIR DEVICE CHORDART**

**Radolfzell/Berlin, January 10<sup>th</sup>, 2025 – CoreMedic GmbH has entered into a strategic partnership with InnoRa GmbH, Berlin, to accelerate clinical development of its transcatheter mitral valve repair solution ChordArt.**

InnoRa GmbH contributes over 20 years of experience in the development of innovative cardiovascular devices and their translation into clinical trials to the partnership. The partnership also includes an undisclosed investment by InnoRa. Professor Bruno Scheller, a renowned expert in interventional cardiology and co-founder of InnoRa will join the Supervisory Board of CoreMedic.

Josef Bogenschütz, CEO of Coremedic GmbH, stated: “We are thrilled to embark on our partnership with InnoRa. We are developing ChordArt™ to offer a superior catheter-based therapy solution for the large and growing population of patients suffering from degenerative mitral valve regurgitation. Under our new partnership, we will jointly deploy our complementary resources to accelerate clinical development of ChordArt.

Jodi Akin, Chairwoman of the Supervisory Board of CoreMedic GmbH stated: “Professor Scheller is a globally renowned expert in interventional cardiology. This comes at the exciting inflection point of our First in Human clinical trial in Europe. We are delighted that Professor Scheller will join the Supervisory Board of CoreMedic and contribute his outstanding scientific and clinical expertise to the company.”

### **About CoreMedic GmbH**

CoreMedic GmbH is an innovative cardiology company, located in Radolfzell, Germany. As a spin-off of the Heart Center of University of Bern, Switzerland, CoreMedic was initiated in 2012 to develop the breakthrough treatment concept for mitral valve regurgitation ChordArt. The company is backed by a group of experienced and committed private investors with backgrounds in heart medicine and cardiovascular devices and institutional healthcare investor SHS Capital.

### **About InnoRa GmbH**

InnoRa is a German medical device company headquartered in Berlin that specializes in the research, development and manufacturing of coated balloon catheters, stents and other medical devices. InnoRa has been providing innovative solutions to improve the life quality of patients for over two decades. Founded in 2001 by scientists as a spin-off of Charité University Hospital, Berlin, Germany, InnoRa’s top priorities are research, development and the provision of high-quality services in the field of cardiovascular innovations.

### **About ChordArt**

The ChordArt Transcatheter Mitral Valve repair (TMVr) - System is designed to improve chorda repair procedures across all crucial parameters. These include the reduction of patient trauma, duration of procedure and complexity as well as operator dependency and time of recovery for the patient. ChordArt is a catheter designed to deliver implants percutaneously allowing interventions in high-risk as well as asymptomatic patients,



which are not eligible for treatment with the current "Gold Standard" of chordal replacement via open-heart surgery.

For further information, please visit [www.coremedic.de](http://www.coremedic.de) or feel free to contact us via [info@coremedic.de](mailto:info@coremedic.de) or under +49 171 426 9395.

PR Contact:  
Thomas Bauer, Managing Director  
CoreMedic GmbH  
Fritz-Reichle-Ring 2  
78315 Radolfzell  
GERMANY